Regional treatment options for patients with ocular melanoma metastatic to the liver

被引:71
作者
Feldman, ED [1 ]
Pingpank, JF [1 ]
Alexander, HR [1 ]
机构
[1] NCI, Surg Metab Sect, Surg Branch, NIH, Bethesda, MD 20892 USA
关键词
regional therapy; liver metastases; chemoembolization; isolation perfusion; intra-arterial chemotherapy; immunotherapy;
D O I
10.1245/ASO.2004.07.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ocular melanoma is the most common primary ocular malignancy and has a significant predilection for metastasis to the liver. More than 40% of patients have hepatic metastases present at initial diagnosis, and the liver becomes involved in up to 95% of individuals who develop metastatic disease. The median survival of patients after diagnosis of liver metastasis ranges from 2 to 7 months. Metastatic disease localized to the liver has proven to be resistant to most available chemotherapy and immunotherapy regimens. Recognition of the grave prognosis associated with liver metastasis from ocular melanoma has led to the evaluation of new regional treatment modalities primarily designed to control tumor progression in the liver, including hepatic arterial chemotherapy, hepatic artery chemoembolization, regional immunotherapy, isolated hepatic perfusion, and percutaneous hepatic perfusion. This article reviews the efficacy, outcomes, and morbidities of the multiple locoregional therapies available today.
引用
收藏
页码:290 / 297
页数:8
相关论文
共 63 条
[1]  
Albert DM, 1996, ARCH OPHTHALMOL-CHIC, V114, P107
[2]  
Alexander HR, 2000, CLIN CANCER RES, V6, P3062
[3]  
Alexander HR, 2003, CLIN CANCER RES, V9, P6343
[4]  
Alexander HR, 1998, CANCER J SCI AM, V4, P2
[5]   Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver [J].
Alexander, HR ;
Bartlett, DL ;
Libutti, SK ;
Fraker, DL ;
Moser, T ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1479-1489
[6]  
Aoyama T, 2000, CANCER, V89, P1561, DOI 10.1002/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO
[7]  
2-R
[8]  
AUSMAN RK, 1961, NEW YORK STATE J MED, V61, P3993
[9]   Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2 [J].
Becker, JC ;
Terheyden, P ;
Kämpgen, E ;
Wagner, S ;
Neumann, C ;
Schadendorf, D ;
Steinmann, A ;
Wittenberg, G ;
Lieb, W ;
Bröcker, EB .
BRITISH JOURNAL OF CANCER, 2002, 87 (08) :840-845
[10]  
BEDIKIAN AY, 1995, CANCER, V76, P1665, DOI 10.1002/1097-0142(19951101)76:9<1665::AID-CNCR2820760925>3.0.CO